Oxford Biomedica cuts 2026 revenue guidance as clients delay orders

Oxford BioMedica PLC (LSE:OXB), the cell and gene therapy manufacturer, has cut its revenue guidance for 2026 after clients deferred orders and a US site took longer than expected to come online. The company now expects full-year revenues of £180 million to £200 million.

Related Symbols 1

O OXB OXB

Source: Proactive Investors

Visit Source

0 0 0

Comment

Important Notice: More than 48 hours have passed since this news or analysis was published. Due to the volatility of financial markets, some of the information or data presented may no longer be valid or reflect current market conditions. Please verify the information again before making any trading or investment decisions.

Comments

No comments yet

Be the first person to comment on this news item.

Category Stock

Source Proactive Investors

Published 1 month ago

Likes 0

Comments 0

Shares 0

News ID #2,753

Status Published

This news may have been collected automatically from third-party sources. Please verify important information through the original source and other reliable sources before making any trading or investment decision. This content is provided for informational purposes only and does not constitute financial advice.

Keep comments relevant to the news topic and avoid offensive, promotional, spam, or misleading content.